Tobacco smoking is the most important preventable cause of cardiovascular disease. In this paper we review current epidemiological and pathophysiological evidence linking smoking with cardiovascular and metabolic diseases. Among the effects of smoking there is the alteration of lipid metabolism through the increase in lipolysis, insulin resistance and tissue lipotoxicity. Smoking is both prothrombotic and atherogenic. As an effect, the risk of acute myocardial infarction, sudden cardiac death, stroke, aortic aneurysm and peripheral vascular disease is increased. Even very low doses of exposure increase the risk of cardiovascular disease (CVD) and metabolic alterations. On the other hand, smoking cessation restores, at least in part, lipid metabolism and the benefits can be observed already after a short period of abstinence from smoking, although it occurs several years before the risks approach those of the never-smoker. © 2010 Bentham Science Publishers Ltd.

Impact of tobacco smoking on lipid metabolism, body weight and cardiometabolic risk / A. Gastaldelli, F. Folli, S. Maffei. - In: CURRENT PHARMACEUTICAL DESIGN. - ISSN 1381-6128. - 16:23(2010), pp. 2526-2530.

Impact of tobacco smoking on lipid metabolism, body weight and cardiometabolic risk

F. Folli
Secondo
;
2010

Abstract

Tobacco smoking is the most important preventable cause of cardiovascular disease. In this paper we review current epidemiological and pathophysiological evidence linking smoking with cardiovascular and metabolic diseases. Among the effects of smoking there is the alteration of lipid metabolism through the increase in lipolysis, insulin resistance and tissue lipotoxicity. Smoking is both prothrombotic and atherogenic. As an effect, the risk of acute myocardial infarction, sudden cardiac death, stroke, aortic aneurysm and peripheral vascular disease is increased. Even very low doses of exposure increase the risk of cardiovascular disease (CVD) and metabolic alterations. On the other hand, smoking cessation restores, at least in part, lipid metabolism and the benefits can be observed already after a short period of abstinence from smoking, although it occurs several years before the risks approach those of the never-smoker. © 2010 Bentham Science Publishers Ltd.
Insulin resistance; Lipolysi; Nicotine; Tobacco smoking; Drug Discovery3003 Pharmaceutical Science; Pharmacology
Settore MED/09 - Medicina Interna
2010
Article (author)
File in questo prodotto:
File Dimensione Formato  
smoking review bentham - Current Pharmaceutical Design.pdf

accesso riservato

Tipologia: Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione 2.3 MB
Formato Adobe PDF
2.3 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/469091
Citazioni
  • ???jsp.display-item.citation.pmc??? 18
  • Scopus 46
  • ???jsp.display-item.citation.isi??? 39
  • OpenAlex ND
social impact